We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Alnylam Signs Licensing Agreement with GeneDesign
News

Alnylam Signs Licensing Agreement with GeneDesign

Alnylam Signs Licensing Agreement with GeneDesign
News

Alnylam Signs Licensing Agreement with GeneDesign

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alnylam Signs Licensing Agreement with GeneDesign"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alnylam Pharmaceuticals, Inc. and GeneDesign, Inc. announced that Alnylam has granted GeneDesign a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.

"Obtaining a license to the Kreutzer-Limmer patent estate allows us to augment our RNAi products, thereby strengthening our position in the life sciences marketplace in Asia," said Kazuhiko Yuyama, President of GeneDesign. "This agreement with Alnylam, a leader in the field of RNAi, reinforces our ability to become a leading supplier of innovative reagent products to the pharmaceutical and research community."

Advertisement